Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
[HTML][HTML] Tumor microenvironment: a new treatment target for cancer
MJ Tsai, WA Chang, MS Huang, PL Kuo - … Scholarly Research Notices, 2014 - hindawi.com
Recent advances in cancer therapy encounter a bottleneck. Relapsing/recurrent disease
almost always developed eventually with resistance to the initially effective drugs. Tumor …
almost always developed eventually with resistance to the initially effective drugs. Tumor …
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
M Juchum, M Günther, SA Laufer - Drug Resistance Updates, 2015 - Elsevier
Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …
Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who …
Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …
G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
CircRNAs and lung cancer: biomarkers and master regulators
X Di, X Jin, R Li, M Zhao, K Wang - Life sciences, 2019 - Elsevier
CircRNAs are a class of competitive, endogenous, non-coding RNAs with closed-loop
structures. High-throughput sequencing indicates that circRNAs are ubiquitously expressed …
structures. High-throughput sequencing indicates that circRNAs are ubiquitously expressed …
Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide …
T Goldkorn, S Filosto, S Chung - Antioxidants & redox signaling, 2014 - liebertpub.com
Chronic obstructive pulmonary disease (COPD) and lung cancer are frequently caused by
tobacco smoking. However, these diseases present opposite phenotypes involving redox …
tobacco smoking. However, these diseases present opposite phenotypes involving redox …
Current approaches in NSCLC targeting K-RAS and EGFR
V Aran, J Omerovic - International journal of molecular sciences, 2019 - mdpi.com
The research and treatment of non-small cell lung cancer (NSCLC) have achieved some
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …
important advances in recent years. Nonetheless, the overall survival rates for NSCLC …
The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells
NA Joseph, SH Chiou, Z Lung, CL Yang, TY Lin… - Journal of Hematology & …, 2018 - Springer
Background Epithelial-to-mesenchymal transition (EMT) has, in recent years, emerged as an
important tumor cell behavior associated with high metastatic potential and drug resistance …
important tumor cell behavior associated with high metastatic potential and drug resistance …